The global digital pathology market size was valued at USD 1.47 billion in 2025 and is projected to grow from USD 1.59 billion in 2026 to USD 3.05 billion by 2034, registering a CAGR of 8.43% during the forecast period from 2026 to 2034. North America dominated the digital pathology market with a market share of 41.6% in 2025.
Digital pathology refers to the acquisition, management, analysis, storage, and interpretation of pathology information using digitized glass slides, whole slide imaging scanners, image management software, artificial intelligence algorithms, cloud-based platforms, and digital workflow tools.
Download a Free Sample To learn more about this report,
Integration of Artificial Intelligence in Digital Pathology
The growing volume of whole-slide images and demand for faster, consistent tissue assessment are encouraging the integration of artificial intelligence into digital pathology workflows. The FDA qualified the AI-based AIM-NASH tool in 2025 to help pathologists assess liver biopsy features in MASH clinical trials, showing how AI can support standardized histologic evaluation while keeping pathologists responsible for final interpretation. This transition can improve quantitative image assessment and support more efficient diagnostic and clinical research workflows.
Adoption of Whole-Slide Imaging for Routine Diagnosis
The need for accessible, high-resolution digital examination of tissue samples is supporting the adoption of whole-slide imaging for clinical pathology workflows. FDA classifications recognize whole-slide imaging systems and digital pathology viewing software as technologies that allow pathologists to review scanned pathology slides for primary diagnosis, while recent research highlights their use in clinical diagnostics and remote collaboration. This shift can reduce dependence on conventional microscope-based workflows and support digital consultation, image sharing, and integration with AI-based analysis.
Remote Consultation and Centralized Pathology Services Drive Market
The need for specialist pathology expertise across geographically separated healthcare facilities creates requirements for digital systems that support remote case review. The FDA recognizes digital pathology as a clinical technology that can support remote access to pathology images and diagnostic information, while its guidance addresses digital pathology systems used for primary diagnosis. For example, a regional hospital can share a complex biopsy case with a specialist at a larger medical center for a second opinion without transferring the physical glass slide. This consultation requirement supports the use of digital pathology platforms and encourages providers to supply secure image-sharing and remote review solutions.
The need for consistent pathology expertise across multiple healthcare facilities creates a preference for centralized laboratory workflows that consolidate specialized resources and case review. NCI's pathology shared resources provide centralized pathology services and expertise for cancer research, including tissue processing, histology, and pathology consultation. For example, a hospital network can route selected pathology cases from smaller facilities to a central laboratory for specialist review and reporting through digital systems. This operating model supports investment in digital pathology infrastructure and creates requirements for image management, data storage, and secure case-sharing systems.
Reimbursement and Image Quality Challenges Restrain Market Expansion
Limited reimbursement for digital pathology services can reduce the financial incentive for laboratories and healthcare providers to invest in scanners, software, storage, and related infrastructure. The absence of clear or adequate payment policies can make it more difficult for providers to recover the costs of digital implementation and ongoing operation. This financial barrier can delay adoption and slow the growth of the digital pathology market.
Scanner and image quality variability can arise from differences in resolution, color reproduction, focusing accuracy, image processing, and tissue preparation across digital pathology systems. FDA identifies technical performance areas such as color reproducibility, spatial resolution, and focusing accuracy as important considerations for whole-slide imaging systems. These variations can increase validation requirements and reduce confidence in consistent diagnostic performance, slowing the adoption of digital pathology technologies.
Digital Pathology Training and Hospital Partnerships Offers Growth Opportunities
Pathologists, laboratory technicians, medical schools, and digital pathology providers can use specialized training resources to build skills in digital workflows and slide interpretation. Leica biosystems provides webinars and educational resources covering digital pathology adoption and implementation, creating revenue through training programs, professional education, and related support services.
Digital pathology companies and hospitals can collaborate on system deployment, workflow integration, training, and long-term support. Philips partnered with saint-joseph and marie-lannelongue hospitals to integrate digital pathology into their enterprise imaging workflow, with the hospitals processing more than 150,000 histology slides annually, creating revenue through scanners, software, implementation, and support services.
System Integration and Image Data Management Hinders Growth
Digital pathology platforms must integrate with laboratory information systems, electronic health records, image-management systems, and existing laboratory workflows. Proprietary data formats and interoperability challenges between whole-slide imaging components can increase customization and implementation requirements. These integration requirements can increase costs and slow deployment across healthcare organizations.
Whole-slide images generate large digital files that require substantial storage, backup, retrieval, and archiving infrastructure. The large size of digital pathology images can increase IT requirements as laboratories expand their digital slide libraries. These requirements can increase infrastructure expenditure and make large-scale deployment more difficult for laboratories with limited digital capabilities.
The device segment accounted for a share of 46.8% in 2025, owing to its essential role in digital slide acquisition, pathology workflow integration, and efficient diagnostic analysis. the increasing adoption of digital pathology solutions, growing demand for faster diagnostic processes, and need for improved laboratory efficiency further strengthen the segment’s dominant position in the digital pathology market.
The software segment is expected to grow at a CAGR of 10.4% during the forecast period 2026-2034, driven by increasing adoption of digital workflow platforms, growing integration of artificial intelligence in pathology, and rising demand for automated image analysis and data management. the scanners segment supports digital slide conversion and high-resolution image acquisition, enabling pathologists to access and analyze tissue samples digitally.
The slide management systems segment facilitates organized handling, tracking, and retrieval of digital pathology slides, supporting efficient laboratory workflows. the storage system segment provides secure and scalable infrastructure for managing large volumes of high-resolution pathology images, while increasing data generation and long-term archiving requirements further support its adoption.
Request Customizationto receive a tailored report.
The human pathology segment accounted for a 91.3% share in 2025 and is expected to grow at a CAGR of 9.4% during the forecast period 2026-2034, owing to the extensive use of digital pathology technologies in disease diagnosis, cancer screening, tissue analysis, and clinical decision-making. the increasing adoption of digital workflows, growing pathology workloads, and demand for efficient diagnostic processes further strengthen the segment’s dominant position in the digital pathology market.
The veterinary pathology segment supports digital diagnostic workflows for animal healthcare by enabling efficient examination, documentation, and analysis of tissue samples. the growing adoption of advanced veterinary diagnostic technologies and increasing demand for accurate animal disease detection continue to support the segment.
The disease diagnosis segment accounted for a share of 42.6% in 2025 due to the increasing need for accurate and efficient diagnostic procedures, growing adoption of digital pathology workflows, and rising demand for faster analysis of tissue samples. the integration of digital imaging, automated analysis, and artificial intelligence further strengthens the segment’s dominant position in the digital pathology market.
The drug discovery & development segment is expected to grow at a CAGR of 9.8% during the forecast period 2026-2034, fueled by increasing use of digital pathology in preclinical research, drug development, and biomarker evaluation. the academic research segment supports digital pathology adoption through advanced tissue analysis, research collaboration, and development of new diagnostic methods.
The others segment includes applications such as pharmaceutical quality assessment, clinical trials, and specialized pathology workflows. the growing use of digital imaging and automated analysis across these applications continues to support demand for digital pathology solutions.
The hospitals segment accounted for a share of 38.9% in 2025, supported by the growing adoption of digital pathology for faster diagnosis, efficient pathology workflows, and improved management of large volumes of tissue samples. the increasing need for advanced diagnostic infrastructure, integration of digital imaging technologies, and demand for streamlined clinical workflows further strengthen the segment’s dominant position in the digital pathology market.
The biotech & pharma companies segment is expected to grow at a CAGR of 9.9% during the forecast period 2026-2034, propelled by increasing use of digital pathology in drug discovery, preclinical research, biomarker analysis, and pharmaceutical development. the diagnostic labs segment supports market adoption through high-volume sample processing, digital slide analysis, and growing demand for efficient diagnostic services.
The academic & research institutes segment supports digital pathology adoption through pathology research, medical education, tissue analysis, and development of advanced diagnostic techniques. the increasing use of digital platforms for collaborative research and remote access to pathology data further supports demand across research institutions.
Speak to an Analystto discuss market opportunities.
The North America digital pathology market accounted for the largest regional share of 41.6% in 2025, supported by advanced healthcare infrastructure, increasing adoption of digital diagnostic technologies, and strong investments in pathology digitization. The U.S. digital pathology market is supported by continued regulatory development of whole-slide imaging and AI-enabled pathology technologies. The FDA’s digital pathology device database was updated in september 2026, including an AI-based digital pathology image artifact detection software classified as a Class II device for identifying artifacts in scanned whole-slide pathology images before diagnostic review. The FDA also maintains a Class II classification for digital pathology image viewing and management software used to review and interpret scanned surgical pathology slides, supporting continued clinical integration of digital pathology technologies in the U.S.
The Canada digital pathology market is supported by increasing integration of digital pathology into diagnostic workflows and the development of technologies for whole-slide image quality control. In march 2026, ontario-based huron technologies filed a canadian trademark application for slideqc, a digital pathology accessory and software application designed to perform manual and automated quality control of whole-slide images and support rescanning of pathology slides that fail quality checks. In addition, the canadian institutes of health research lists research funding involving digital pathology and AI-based analysis of digital bladder-cancer tissue images, supporting the development of AI-assisted diagnostic applications in Canada.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific digital pathology market is expected to grow at a CAGR of 11.6% during the forecast period 2026-2034, showcasing the fastest-growing regional market, fueled by expanding healthcare infrastructure, rising demand for efficient diagnostic solutions, and increasing adoption of artificial intelligence-enabled pathology systems.
The Japan digital pathology market is supported by continued integration of AI and whole-slide imaging into pathology workflows, particularly for cancer diagnosis and diagnostic assistance. The China digital pathology market is driven by rapid development of digital pathology networks and AI-assisted diagnostic technologies, owing to growing adoption across regional pathology centers, cloud-based diagnostic networks, and AI-based pathology applications.
The South Korea digital pathology market is due to an established regulatory framework for AI-based tissue pathology in vitro diagnostic software, with 2026 regulatory developments strengthening the approval and evaluation of digital medical devices. The India digital pathology market is fueled by increasing integration of AI with pathology and cancer diagnostics, supported by government-backed initiatives advancing digital slide imaging, AI-assisted screening, remote pathology analysis, and centralized healthcare data workflows.
The Europe digital pathology market accounted for a regional share of 27.4% in 2025, owing to growing adoption of digital pathology workflows, established healthcare systems, and increasing investments in advanced diagnostic technologies.
In the U.K. digital pathology market, accelerating digital transformation across NHS pathology services is supporting adoption. In 2026, NHS england reported that university college london hospitals had gone live with digital pathology as part of a coordinated north central london rollout, with digital images supporting diagnosis and reporting in nearly 70% of histopathology cases within weeks of implementation. The 2026 national cancer plan also commits £604 million in capital investment in digital diagnostics, including digital pathology, alongside £96 million for histopathology automation, supporting wider adoption of digital pathology and AI-enabled workflows.
In the Germany digital pathology market, growing integration of artificial intelligence and image analysis into pathology research and diagnostics is supporting market development. In 2026, fraunhofer IIS showcased its MIKAIA digital pathology platform at the german society of pathology's annual meeting, providing whole-slide and batch analysis, AI-model training, and analysis across H&E, IHC, multiplex immunofluorescence, and other modalities. In the France digital pathology market, government efforts are accelerating the digital transformation of anatomical and cytological pathology. The french ministry of health's national digital pathology roadmap calls for faster deployment of digital pathology, preparation for the integration of artificial intelligence into medical practice, and stronger laboratory infrastructure through investment in scanners, software, servers, and storage solutions.
The Middle East and Africa digital pathology market is expected to grow at a CAGR of 7.9% during the forecast period 2026-2034, driven by healthcare modernization, expanding diagnostic capabilities, and rising adoption of digital healthcare technologies. The UAE digital pathology market is expected to benefit from the country’s growing adoption of AI-enabled healthcare, advanced diagnostics, and data-driven precision medicine. In 2026, the department of health – abu dhabi highlighted AI, advanced genetics, data analytics, and early intervention as key components of its healthcare strategy, while the emirate’s life-sciences ecosystem integrates population-scale genomics, health data, research capabilities, and AI-enabled technologies. These developments are expected to support the adoption of digital pathology, image analysis, and AI-assisted diagnostic workflows.
The Africa digital pathology market is expected to benefit from efforts to expand pathology capacity and improve access to advanced cancer diagnostics. In 2026, WHO highlighted that access to pathology remains extremely limited in many african settings, while the international agency for research on cancer (IARC) continues to advance digital pathology and image-based pathology reviews through its histopathology laboratory and international collaborations. The growing use of digital pathology, tele-expertise, and AI-assisted diagnostic workflows is expected to support more accessible and scalable pathology services across Africa.
The digital pathology market is moderately fragmented, with medical imaging companies, pathology solution providers, healthcare technology companies, laboratory equipment manufacturers, software developers, and specialized digital pathology technology providers competing across hospitals, diagnostic laboratories, research institutions, pharmaceutical companies, and academic settings. Established players compete primarily on image quality, scanner accuracy, workflow efficiency, software capabilities, artificial intelligence integration, interoperability, data security, regulatory compliance, research and development, product reliability, and global distribution networks. The leading players in the digital pathology market include oracle health, philips healthcare, siemens healthineers, GE healthcare, and tempus AI, with the top five players estimated to account for approximately 35% of the global market based on their healthcare technology portfolios, digital capabilities, imaging expertise, geographic presence, and competitive positioning.
Emerging and regional players compete through cost-effective solutions, compact scanning technologies, cloud-based platforms, AI-enabled image analysis, customized software, interoperable systems, flexible deployment models, localized support, and rapid product development within the digital pathology market ecosystem. These players also focus on developing AI-enabled pathology tools, improving image analysis capabilities, and expanding cloud-based and interoperable solutions to differentiate their offerings and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Artificial Intelligence for Drug Discovery and Development Market Size, 2034
Big Data in Healthcare Market Size, Share, Growth, Analysis, 2034
Healthcare Human Resources Software Market Size, Share, 2034
Meditation Management Apps Market Size, Share, Growth, Analysis, 2034
Cloud Based Drug Discovery Platform Market Size, Forecast, 2034
Ai Based Clinical Trials Solution Provider Market Size, 2034
We are featured on:
sales@straitsresearch.com